Year ALL20202019

Date	Title	Download
02/26/21	Akorn Announces Review of Strategic Alternatives for the Akorn Consumer Health Business
02/11/21	Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Gel, 0.5%
10/28/20	Akorn Announces Its New Board of Directors
10/01/20	Akorn Successfully Completes Sale to Lenders and Exits Chapter 11 Protection
06/22/20	Akorn Animal Health Announces Launch of Neomycin and Polymyxin B Sulfates, and Bacitracin Zinc Ophthalmic Ointment
10/14/19	Akorn Receives FDA Approval for Betamethasone Dipropionate Lotion USP (Augmented), 0.05%
08/26/19	Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.15%
06/28/19	Akorn Announces Launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5%
05/30/19	Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.1%
04/18/19	Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Suspension, 0.5%
04/18/19	Akorn Receives FDA Approval for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC)